AstraZeneca’s Truqap Achieves Phase 3 Success in Prostate Cancer, Paving Way for Label Expansion

Phase 3 Trial Success:
AstraZeneca's Truqap, in combination with abiraterone and androgen deprivation therapy (ADT), has shown positive results in the Phase III CAPItello-281 trial for treating PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC)[1][4][5].

Improved rPFS:
The trial demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to the control group receiving abiraterone, ADT, and placebo[1][4][5].

Potential for Label Expansion:
This success brings Truqap closer to a potential label expansion for prostate cancer, following its current approvals for certain types of breast cancer[2][3].

Ongoing Evaluation:
The trial will continue to evaluate overall survival (OS) as a secondary endpoint, with early trends suggesting potential improvement in OS compared to the control group[1].

Collaborative Development:
Truqap was developed in partnership with Astex Therapeutics, the Institute of Cancer Research, and Cancer Research Technology[1].